Join Minerva Neurosciences for a virtual key opinion leader (KOL) event featuring Gregory Strauss, PhD (Franklin Professor of Psychology, University of Georgia) and Brian Kirkpatrick, MD, MSPH (Peters Professor of Psychiatry, University of Arkansas for Medical Sciences), who will join the company management team to elaborate on the patient burden of the negative symptoms of schizophrenia, the challenges associated with assessing negative symptoms in the current regulatory environment and how the company’s upcoming Phase 3 trial of roluperidone is expected to meet those challenges.

Current antipsychotics do not adequately treat the negative symptoms of schizophrenia despite decades of clinical trials and myriad FDA approvals. Recognizing there has never been a drug approved specifically for negative symptoms, FDA hosted a public meeting in August 2024 to establish the optimal approach in clinical trials. Minerva plans to start a confirmatory Phase 3 trial in 2026 utilizing a novel protocol, which is aligned with FDA considerations and designed to maximize the probability of a successful outcome.

A live question and answer session will follow the formal presentations.